Shield Therapeutics plc

Company Profile

Company website
Pharmaceuticals & Biotechnology (Pharmaceuticals)

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.

Accrufer®/Feraccru® has patent coverage until the mid-2030s

Accrufer®/Feraccru® are registered trademarks of the Shield Group

Investor Access

30 Jun
Event information

Management will hold a presentation for Investors through the digital platform, Investor Meet Company, at 4:30pm on 30 Jun 2022 relating to the final results for the year ended 31 December 2021.

Investors can sign up to Investor Meet Company for free, by clicking here

30th June 2022 at 4:30pm
Financial Calendar
 Event  Date
Year End 31 December
Half  Year End 30 June
Preliminary Results* May
Interim Results* September
AGM* June

* Months based on previous announcements of this kind